Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Completed · Phase 3

Conditions studied: Major Depressive Disorder

In brief

The purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.

Key facts

Study ID
NCT00095134
Run by
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
People needed
630
Starts
2004-10-01
Expected to finish
2005-11-01
Last updated by the study team
2011-12-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.